Benzinga··Vandana SinghTakeda Exits Dementia Drug Partnership With Denali in Strategic Shift
Takeda exits dementia drug partnership with Denali Therapeutics on DNL593. Denali regains full control, plans Phase 1/2 data release by end-2026. Denali shares fell 3.73%.
TAKDNLIPhase 1/2 trialbiotech collaboration